TY - JOUR
T1 - Ondansetron in the treatment of cognitive decline in Alzheimer dementia
AU - Dysken, Maurice
AU - Kuskowski, Michael
AU - Love, Susan
AU - Billig, Nathan
AU - Borison, Richard
AU - Doody, Rachelle
AU - Drachman, David
AU - DeBoff, Eugene
AU - Dunner, David
AU - Farmer, Mildred
AU - Finkel, Sanford
AU - Foster, Norman
AU - Freeman, Arthur
AU - Graff-Radford, Neill
AU - Green, Robert
AU - Grossberg, George
AU - Hendrie, Hugh
AU - Jagust, William
AU - Jenkyn, Lawrence
AU - Morris, John
AU - Preskorn, Sheldon
AU - Sano, Mary
AU - Seltzer, Benjamin
AU - Tuttle, Paul
N1 - Funding Information:
This work was supported by a grant from the Glaxo Research Institute. The authors thank Joseph De Veaugh-Geiss, M.D., Alan Metz, M.D., Frank Stallone, Ph.D., and Joanne Cedrone, R.N., M.A., for their contributions to this study.
PY - 2002
Y1 - 2002
N2 - The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 μg/day and 100 μg/day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.
AB - The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 μg/day and 100 μg/day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.
UR - http://www.scopus.com/inward/record.url?scp=17444438273&partnerID=8YFLogxK
U2 - 10.1097/00019442-200203000-00013
DO - 10.1097/00019442-200203000-00013
M3 - Article
AN - SCOPUS:17444438273
SN - 1064-7481
VL - 10
SP - 212
EP - 215
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 2
ER -